This inventor holds 5 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Millennium Pharmaceuticals Limited. Active years: 2001-2009.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Dorchester, MA (US) (2001 - 2005)
- Stanford, CA (US) (2008 - 2009)
Company Filing History:
Years Active: 2001-2009
Title: Innovator Brian A. Zabel: Pioneering Anti-Inflammatory Treatments
Introduction
Brian A. Zabel, hailing from Stanford, CA, has emerged as a significant figure in the realm of biomedical innovation. With a remarkable portfolio of five patents, Zabel's work focuses primarily on methods for treating inflammatory diseases, utilizing cutting-edge antibody technology.
Latest Patents
His latest patents exemplify his innovative approach to tackling inflammatory diseases. One notable patent describes methods of treating such conditions using antibodies that bind to the CC chemokine receptor GPR-9-6. This invention details an antibody or its antigen-binding fragment that can block the binding of ligands like TECK to GPR-9-6. Additionally, the patent outlines methods to identify potential agents that can bind to GPR-9-6, thus inhibiting ligand binding and modulating receptor function.
Another important patent includes the development of anti-TECK antibodies, which inhibit the binding of the chemokine TECK to GPR-9-6. This innovation further provides insights into host cells that produce such antibodies, as well as kits and methods of use for these antibodies and their fragments.
Career Highlights
Zabel works at Millennium Pharmaceuticals Limited, a reputable company known for its contributions to the pharmaceutical industry. His role at the company allows him to collaborate with cutting-edge researchers and contribute significantly to advancements in therapeutic solutions.
Collaborations
Throughout his career, Brian has worked alongside notable colleagues, including David P. Andrew and Paul D. Ponath. These collaborations have fostered a dynamic environment for innovation, enhancing the impact of their collective research endeavors on the biomedical field.
Conclusion
Brian A. Zabel remains a trailblazer in the pursuit of new therapeutic methods for treating inflammatory diseases. With his groundbreaking patents and collaborations at Millennium Pharmaceuticals Limited, Zabel's work continues to have a lasting impact on both scientific research and clinical applications in the fight against inflammation-related ailments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile